DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR PYRIDOSTIGMINE BROMIDE
» See Plans and Pricing
All Clinical Trials for Pyridostigmine Bromide
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00953914 | Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients | Completed | Hospital de Clinicas de Porto Alegre | N/A | 2005-03-01 | The purpose of the study is to determine if pyridostigmine bromide improves heart rate variability of type 2 diabetes mellitus subjects with cardiovascular autonomic neuropathy. |
NCT01765140 | Treatment Use of 3,4-Diaminopyridine | Available | Vern C. Juel, M.D. | N/A | 1969-12-31 | This is a continuing project to provide 3,4 diaminopyridine (DAP) under a treatment-use IND to patients with Lambert-Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndrome (CMS). |
NCT01855217 | Pilot Study on the Pharmacodynamics of Sugammadex in Morbidly Obese Patients: Reversal of Deep Neuromuscular Blockade | Unknown status | St. Antonius Hospital | Phase 3 | 2013-04-01 | Should the dose of sugammadex in morbid obese patients be calculated on the real body weight or the ideal body weight? To study the pharmacodynamics of sugammadex in morbidly obese patients by comparing 1 mg/kg IBW versus 1 mg/kg TBW versus placebo. |
NCT01993680 | Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment | Active, not recruiting | University of Zurich | Phase 2 | 2012-06-01 | Disabling symptoms of blood pressure dysregulation, impaired swallowing and digestion are common amongst Parkinson`s patients. So far the exact pathophysiology for this is not fully understood. There are results from pathological analyses that the autonomic nervous system is also affected by the accumulation of alpha-Synuclein and that this might even happen in very early stages of the disease process (Qualman et al., 1984; Wakabayashi et al., 1989; Wakabayashi et al., 1990; Bloch et al., 2006). Blood pressure dysregulation is a common autonomic symptom in Parkinson`s patients and treatment - currently most often achieved with Fludrocortisone - often leads to supine hypertension (Plaschke et al., 1998; Braune et al., 1999; Magerkurth et al., 2005). There are studies in patients with autonomic failure that indicate that Pyridostigmine bromide might be an alternative treatment option without causing disabling supine hypertension (Singer et al., 2003; Sandroni et al., 2005; Singer et al., 2006; Yamamoto et al., 2006). Delayed gastric emptying is also an autonomic symptom associated with Parkinson`s disease. By the elevation of the cholinergic tone with Pyridostigmine bromide the investigators also expect to alleviate symptoms of delayed gastric emptying and obstipation, possibly even facilitating the uptake of dopaminergic medication through the gut (Sadjadpour, 1983; Bharucha et al., 2008). Therefore the investigators designed a monocentric randomized, controlled, double blind, crossover phase II trial to show non-inferiority of the effect of pyridostigmine bromide vs. fludrocortisone on symptoms of autonomic dysregulation in Parkinson`s disease. |
NCT02206490 | Trial of Naltrexone and Dextromethorphan for Gulf War Illness | Completed | East Carolina University | Phase 2 | 2012-01-01 | Veterans of the 1991 Gulf War who developed Gulf War Illness are being studied. Treatments with FDA approved generic drugs are being administered to see if they help with the symptoms of Gulf War Illness, such as chronic fatigue; difficulty with memory, concentration, and thinking; widespread chronic pain; and autonimic dysfunction. Drugs to be tested are dextromethorphan and naltrexone. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Pyridostigmine Bromide
Condition Name
Clinical Trial Locations for Pyridostigmine Bromide
Trials by Country
Clinical Trial Progress for Pyridostigmine Bromide
Clinical Trial Phase
Clinical Trial Sponsors for Pyridostigmine Bromide
Sponsor Name
Sponsor Name for Pyridostigmine Bromide | |
Sponsor | Trials |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 2 |
James J. Peters Veterans Affairs Medical Center | 1 |
Michael Debakey Veterans Affairs Medical Center | 1 |
[disabled in preview] | 2 |
This preview shows a limited data set Subscribe for full access, or try a Trial |